Barclays PLC Sells 1,557 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Barclays PLC cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,419 shares of the medical research company's stock after selling 1,557 shares during the period. Barclays PLC owned about 0.14% of Bio-Rad Laboratories worth $13,278,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BIO. Venturi Wealth Management LLC raised its holdings in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after buying an additional 87 shares during the last quarter. Picton Mahoney Asset Management grew its stake in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc bought a new position in Bio-Rad Laboratories during the 4th quarter worth $33,000. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. bought a new position in shares of Bio-Rad Laboratories during the fourth quarter worth about $38,000. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

NYSE:BIO traded down $10.61 during trading hours on Friday, reaching $239.13. The stock had a trading volume of 147,294 shares, compared to its average volume of 314,073. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a market cap of $6.70 billion, a P/E ratio of -3.68 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a 12-month low of $215.38 and a 12-month high of $387.99. The stock has a 50 day simple moving average of $251.85 and a 200 day simple moving average of $309.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

BIO has been the subject of a number of analyst reports. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Wells Fargo & Company lowered their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories has an average rating of "Moderate Buy" and an average price target of $380.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.